Cannabidiol clinical trials at UC Davis
1 research study open to eligible people
“Children and teens between 3 and 17 diagnosed with Fragile X syndrome may qualify for a clinical trial”
open to eligible people ages 3-23
This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of Cannabidiol administered as ZYN002 for the treatment of children, adolescent, and young adult patients with Fragile X Syndrome (FXS). Eligible participants will participate in up to an 18-week treatment period, where all participants will receive placebo or active study drug. Patients ages 3 to < 23 years will be eligible to participate.
Sacramento, California and other locations
Our lead scientists for Cannabidiol research studies include Randi Hagerman, MD.